Seminars
Nov 26, 2026
From mice to humans: the underrated Death Valley in neuromuscular disorders clinical development
Speaker: Professor Laurent Servais
Professor of Paediatric Neuromuscular Diseases, University of Oxford & Professor, University of Liège in Belgium
School of Biomedical Sciences cordially invites you to join the following seminar:
Date: 26 November 2026 (Thursday)
Time: 11:30 am – 12:30 pm
Venue: Faculty Boardroom, 1/F, William M.W. Mong Block, 21 Sassoon Road
Hosts: Professor Martin Cheung and Professor Sophelia Chan
Biography
Laurent Servais is Professor of Paediatric Neuromuscular Diseases at the University of Oxford in the UK, and Professor at the University of Liège in Belgium. He graduated in medicine and pediatrics from the University of Louvain (in Louvain-la-Neuve and Brussels in Belgium) then trained as a child neurologist in the Robert Debré Hospital in Paris, France, and as a myologist at the Institute of Myology, Pitié-Salpêtrière University Hospital, Paris.
Professor Servais’ main research interests cover innovative outcome measures and clinical trials design and newborn screening (NBS). He has been involved as Principal Investigator in several clinical trials in spinal muscular atrophy (SMA), Angelman Syndrome X-linked myotubular myopathy, and Duchenne muscular dystrophy (DMD), and in leading the NBS program for SMA NBS in Belgium and in the UK. He is the coordinating investigator of two large natural history studies in Angelman in the UK and in Belgium that aims to identify and validates innovative outcome measures and biomarkers.
Abstract
Despite decades of intensive research and substantial advances in our understanding of neuromuscular disorders (NMDs), the translation of scientific discoveries into effective therapies remains remarkably challenging. Only a limited number of drugs have reached regulatory approval in this field, and, with the notable exception of spinal muscular atrophy (SMA), the clinical benefits of approved treatments have generally been modest.
This persistent gap between promising preclinical findings and meaningful clinical outcomes highlights an often underestimated 'Death Valley' in drug development: the transition from animal models to human patients.
In this presentation, we will explore the potential reasons behind this translational gap. We will first examine the relevance and limitations of animal models, questioning how faithfully they recapitulate human disease pathophysiology and clinical progression. We will then discuss the concept of clinical readiness, including the robustness of preclinical evidence, patient selection and the choice of appropriate clinical outcome measures. Finally, we will address a critical yet frequently overlooked aspect of therapeutic development: the window of efficacy. When is intervention most likely to make a meaningful difference, and are we sometimes testing promising therapies too late in the course of disease?
Understanding these challenges is essential to bridging the translational gap and improving the success rate of future NMD clinical development.
All are welcome.
New Releases
Oct 14, 2026
HKUMed SBMS and E-SENSE Innovation & Technology Forge Strategic Partnership to Advance Biomedical Imaging and Digital Health Solutions
Oct 8, 2026
Hong Kong’s Biotech Ecosystem Gains Momentum: HKUMed and Skyhore Collaborate to Drive Innovation and Cultivate Future Leaders in Microbiome Science
Sep 17, 2026
HKUMed School of Biomedical Sciences and Phase Scientific join forces to nurture Hong Kong's next-generation biomedical talent through academic-industry collaboration
Jun 8, 2026